



(51) International Patent Classification:

A61K 31/7072 (2006.01) C07H 19/04 (2006.01)
A61K 31/7076 (2006.01)

(21) International Application Number:

PCT/US2014/038288

(22) International Filing Date:

15 May 2014 (15.05.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/824,034 16 May 2013 (16.05.2013) US

(71) Applicant: RIBOSCIENCE LLC [US/US]; 3901 Laguna Avenue, Palo Alto, California 94306 (US).

(72) Inventors: SMITH, Mark; 333 Harrison Street, #363, San Francisco, California 94105 (US). KLUMPP, Klaus G.; 611 Winston Lane, West Chester, Pennsylvania 19382 (US).

(74) Agent: KISKO, Jennifer L.; Gray Robinson, P.A., P.O. Box 3068, 301 E. Pine Street, Suite 1400, Orlando, Florida 32802-3068 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: 4'-AZIDO, 3'-DEOXY-3'-FLUORO SUBSTITUTED NUCLEOSIDE DERIVATIVES



I

(57) Abstract: The present disclosure relates to 4'-azido, 3'-deoxy-3'-fluoro substituted nucleoside derivatives as inhibitors of HCV replicon RNA replication. Also disclosed are pharmaceutical compositions comprising such compounds and methods of use thereof for the treatment of HCV.